A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth. Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 15.5%. This drop was worse than the S&P 500’s 10% fall.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Encompass Health (NYSE:EHC) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at outpatient & specialty care stocks, starting with Select Medical (NYSE:SEM).
LifeStance Health Group trades at $6.79 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 7.1% while the S&P 500 is down 8.3%. This may have investors wondering how to approach the situation.
Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Let’s dig into the relative performance of agilon health (NYSE:AGL) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
Looking back on outpatient & specialty care stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including U.S. Physical Therapy (NYSE:USPH) and its peers.
Behavioral health company LifeStance Health (NASDAQ:LFST) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 16% year on year to $325.5 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $330 million was less impressive, coming in 2.3% below expectations. Its GAAP loss of $0.02 per share was $0.02 above analysts’ consensus estimates.
Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company reported on Tuesday its financial results for the three months ended May 31, 2024. The Toronto-based company reported a nearly 50% year-over-year drop in net revenue from continued operations to CA$3.9 million ($2.8 million) in the second quarter of fiscal 2024. Meni Morim, CEO of Lifeist said the company's second-quarter performance "is another clear indication that we must move on from operating our legacy cannabis business segments and find other solutions that have exposure to the broader wellness market."
Shareholders of four cannabis companies held their respective annual meetings, electing nominees as board directors.Sandy Li, who has been serving at cannabis edibles producer Wana Brands since 2022 as CFO joined Viridian Capital Advisors's advisory board. David Vautrinas was appointed to serve as chief retail officer of RIV Capital.
Simply Solventless Concentrates Ltd. (TSXV: HASH) is acquiring Lifeist Wellness Inc.'s (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF) subsidiary CannMart Inc.The Calgary, Alberta-based company said on Wednesday that it has entered into a services agreement regarding the operations of CannMart and a share purchase agreement with Lifeist Wellness Inc. to acquire all of the shares of CannMart.
Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF) said on Wednesday the sale of Australian Vaporizers Pty Ltd., its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ: FLGC).The sale, first announced in September 2023, was wrapped up through a share purchase agreement, under which Lifeist has sold the issued and outstanding shares of Aussie Vapes to Flora, for roughly CA$900,000 ($658,439). The sum is payable by Flora issuing from treasury to Lifeist 550,000 of its common shares.In the meantime,
LifeStance Health shares are trading lower by 19.8% during Wednesday's session. The company announced pricing of a 20 million share offering by selling stockholders.
